IDIOPATHIC PULMONARY FIBROSIS
Clinical trials for IDIOPATHIC PULMONARY FIBROSIS explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC PULMONARY FIBROSIS trials appear
Sign up with your email to follow new studies for IDIOPATHIC PULMONARY FIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple attack on lung scarring: could plasma exchange and immune therapy slow IPF?
Disease control Not yet recruitingThis Phase II trial tests whether a combination of therapeutic plasma exchange (filtering the blood), rituximab (a drug that targets certain immune cells), and intravenous immunoglobulin (IVIg) can slow lung decline in people with progressive idiopathic pulmonary fibrosis (IPF). …
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
Inhaled drug could offer new hope for lung scarring disease
Disease control Not yet recruitingThis phase 2 trial tests whether an inhaled form of nintedanib (MNKD-201) is safe and effective for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring. About 210 adults with IPF will receive either a low or high dose of the inhaled drug or a plac…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: Mannkind Corporation • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
New pill aims to slow lung scarring in IPF patients
Disease control Not yet recruitingThis study tests an experimental tablet called SYH2059 in 156 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing harder. Participants will receive either the drug or a placebo to see if it can slow the decline in lung function. The…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: InnovStone Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could a common diabetes drug help fight a deadly lung disease?
Disease control Not yet recruitingThis study tests whether metformin, a standard diabetes medicine, can slow the worsening of idiopathic pulmonary fibrosis (IPF), a serious lung disease. About 400 high-risk patients will receive either metformin or a placebo. The goal is to see if metformin can delay death, hospi…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE3 • Sponsor: University of Massachusetts, Worcester • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for lung scarring? drug trial aims to slow breathing decline
Disease control Not yet recruitingThis study tests two doses of an experimental drug, zampilimab, against a placebo in 240 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The main goal is to see if the drug can improve lung function over 24 weeks, with an …
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Could a painkiller stop the cough that Won't quit in lung fibrosis?
Symptom relief Not yet recruitingThis study tests whether an extended-release form of nalbuphine, a pain medication, can safely reduce chronic coughing in people with idiopathic pulmonary fibrosis (IPF), a lung scarring disease. About 306 adults with IPF and a cough lasting at least 8 weeks will receive either t…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE3 • Sponsor: Trevi Therapeutics • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
AI model aims to predict lung disease progression
Knowledge-focused Not yet recruitingThis observational study will collect data from 1000 people with idiopathic pulmonary fibrosis (IPF) across multiple Italian centers. Researchers will use machine learning to build a model that predicts disease progression, acute flare-ups, and response to treatment. The goal is …
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Sponsor: University of Modena and Reggio Emilia • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC